First patients test new cancer Drug's safety
NCT ID NCT04362748
Summary
This was an early-stage safety study for a new cancer drug called AMG 256. It involved 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose for future testing and to understand how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Cliniques Universitaires Saint Luc
Brussels, 1200, Belgium
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, 08036, Spain
-
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, 08035, Spain
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Monash Medical Centre
Clayton, Victoria, 3168, Australia
-
St Vincents Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.